scholarly journals Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia

2020 ◽  
Vol 16 (10) ◽  
pp. 1029-1042
Author(s):  
Regina M. Myers ◽  
Joseph Dolan ◽  
David T. Teachey
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
T Cell ◽  
Young Adult ◽  
Cell Therapy ◽  
B Cell ◽  
Chimeric Antigen Receptor ◽  
Lymphoblastic Leukemia ◽  
Antigen Receptor ◽  
T Cell Therapy ◽  
Cell Acute Lymphoblastic Leukemia

scholarly journals Improving and Maintaining Responses in Pediatric B–Cell Acute Lymphoblastic Leukemia Chimeric Antigen Receptor–T Cell Therapy

2021 ◽  
Vol 27 (2) ◽  
pp. 151-158
Author(s):  
Rahul Arya ◽  
David M. Barrett ◽  
Stephan A. Grupp ◽  
Jan Joseph Melenhorst
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
T Cell ◽  
Cell Therapy ◽  
B Cell ◽  
Chimeric Antigen Receptor ◽  
Lymphoblastic Leukemia ◽  
Antigen Receptor ◽  
T Cell Therapy ◽  
Cell Acute Lymphoblastic Leukemia

scholarly journals Cost‐effectiveness of Anti‐CD19 chimeric antigen receptor T‐Cell therapy in pediatric relapsed/refractory B‐cell acute lymphoblastic leukemia. A societal view

2020 ◽  
Vol 105 (2) ◽  
pp. 203-215 ◽  
Author(s):  
Frederick W. Thielen ◽  
Annemieke Dongen‐Leunis ◽  
Alexander M. M. Arons ◽  
Judith R. Ladestein ◽  
Peter M. Hoogerbrugge ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Acute Lymphoblastic Leukemia ◽  
T Cell ◽  
Cell Therapy ◽  
B Cell ◽  
Chimeric Antigen Receptor ◽  
Lymphoblastic Leukemia ◽  
Antigen Receptor ◽  
T Cell Therapy ◽  
Cell Acute Lymphoblastic Leukemia

scholarly journals Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia

2020 ◽  
Vol 38 (5) ◽  
pp. 415-422 ◽  
Author(s):  
Noelle V. Frey ◽  
Pamela A. Shaw ◽  
Elizabeth O. Hexner ◽  
Edward Pequignot ◽  
Saar Gill ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
T Cell ◽  
Cell Therapy ◽  
B Cell ◽  
Chimeric Antigen Receptor ◽  
Therapeutic Potential ◽  
Lymphoblastic Leukemia ◽  
Antigen Receptor ◽  
High Dose ◽  
T Cell Therapy

PURPOSE The anti-CD19 chimeric antigen receptor T-cell therapy tisagenlecleucel (CTL019) has an 81% response rate in children with relapsed or chemotherapy refractory (r/r) B-cell acute lymphoblastic leukemia (ALL). Cytokine release syndrome (CRS) is a life-threatening treatment-related toxicity that limits the full therapeutic potential in adults. We report outcomes for adults with r/r ALL treated with an optimized CTL019 dosing and CRS management strategy. METHODS Adults with r/r B-cell ALL received CTL019 in 1 of 2 trials. Patients received lymphodepletion followed by CTL019 as either a one-time infusion or fractionated infusions split over 3 days (day 1, 10%; day 2, 30%; day 3, 60%), which allowed for day 2 and day 3 doses to be held for early CRS. Total planned CTL019 dose varied with adaptive protocol modifications in response to efficacy and CRS toxicity. RESULTS Thirty-five adults with r/r ALL received CTL019 in 1 of 3 dosing cohorts. The low-dose cohort (n = 9) received single or fractionated dosing and had manageable toxicity with a 33% complete remission (CR) rate. In the high-dose single infusion cohort, 3 of 6 patients with refractory CRS concurrent with culture-positive sepsis died, and 3 achieved CR. The 20 patients in the high-dose fractionated (HDF) cohort had a 90% CR rate and manageable CRS. The HDF cohort had the highest survival, with a 2-year overall survival of 73% (95% CI, 46% to 88%) and event-free survival of 49.5% (95% CI, 21% to 73%). CONCLUSION Fractionated dosing of CTL019 with intrapatient dose modification optimizes safety without compromising efficacy in adults with r/r ALL.

Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Acute Lymphoblastic Leukemia (B-ALL)

2021 ◽  
pp. 179-196
Author(s):  
Geoffrey Shouse ◽  
Elizabeth Budde ◽  
Stephen Forman
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
T Cell ◽  
Cell Therapy ◽  
Chimeric Antigen Receptor ◽  
Lymphoblastic Leukemia ◽  
Antigen Receptor ◽  
T Cell Therapy ◽  
Car T Cell ◽  
Car T Cell Therapy ◽  
Car T
Sign in / Sign up

Export Citation Format

Share Document